ArticleProceedings of the National Academy of Sciences of the United States of America1999
Synergy between an antiangiogenic integrin alphav antagonist and an antibody-cytokine fusion protein eradicates spontaneous tumor metastases.
Article in Proceedings of the National Academy of Sciences of the United States of America, 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 127 citations in OpenAlex.
- Trial
- Article
- Interaction of integrin αFrontiers in cell and developmental biology · 2025Article
- Generation of Novel Immunocompetent Mouse Cell Lines to Model Experimental Metastasis of High-Risk Neuroblastoma.Cancers · 2023Article
- Therapeutic targeting of anoikis resistance in cutaneous melanoma metastasis.Frontiers in cell and developmental biology · 2023Review
- Immunotherapy improves disease prognosis by affecting the tumor microenvironment: A bibliometric study.Frontiers in immunology · 2022Review
- Editorial: A Novel Monoclonal Antibody-Targeting Angiogenesis by Inhibiting Secreted Frizzled-Related Protein 2.Annals of surgical oncology · 2019Article
- Annexin A5 regulates surface αvβ5 integrin for retinal clearance phagocytosis.Journal of cell science · 2019Article
- Activation of Hepatic Stellate Cells During Liver Carcinogenesis Requires Fibrinogen/Integrin αvβ5 in Zebrafish.Neoplasia (New York, N.Y.) · 2018Article
- A phase I study of continuous infusion cilengitide in patients with solid tumors.Investigational new drugs · 2012Article
- Article
- Targeting angiogenesis for controlling neuroblastoma.Journal of oncology · 2012Article
- A human recombinant autoantibody-based immunotoxin specific for the fetal acetylcholine receptor inhibits rhabdomyosarcoma growth in vitro and in a murine transplantation model.Journal of biomedicine & biotechnology · 2010Article
- Molecular ultrasound imaging of early vascular response in prostate tumors irradiated with carbon ions.Neoplasia (New York, N.Y.) · 2009Article
- Syndecan-1 regulates alphavbeta3 and alphavbeta5 integrin activation during angiogenesis and is blocked by synstatin, a novel peptide inhibitor.The Journal of experimental medicine · 2009Article
- Tumor-selective response to antibody-mediated targeting of alphavbeta3 integrin in ovarian cancer.Neoplasia (New York, N.Y.) · 2008Article
- PPARgamma in Neuroblastoma.PPAR research · 2008Article
- Fibroblast migration after myocardial infarction is regulated by transient SPARC expression.Journal of molecular medicine (Berlin, Germany) · 2006Article
- Integrins: molecular targets in cancer therapy.Current oncology reports · 2006Review
- Clinical implications of angiogenesis in cancers.Vascular health and risk management · 2006Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
Abstract
The suppression and eradication of primary tumors and distant metastases is a major goal of alternative treatment strategies for cancer, such as inhibition of angiogenesis and targeted immunotherapy. We report here a synergy between two novel monotherapies directed against vascular and tumor compartments, respectively, a tumor vasculature-specific antiangiogenic integrin alphav antagonist and tumor-specific antibody-interleukin 2 (IL-2) fusion proteins. Simultaneous and sequential combination of these monotherapies effectively eradicated spontaneous liver metastases in a poorly immunogenic syngeneic model of neuroblastoma. This was in contrast to controls subjected to monotherapies with either an antiangiogenic integrin alphav antagonist or antibody-IL-2 fusion proteins, which were only partially effective at the dose levels applied. Furthermore, simultaneous treatments with the integrin alphav antagonist and tumor-specific antibody-IL-2 fusion proteins induced dramatic primary tumor regressions in three syngeneic murine tumor models, i.e., melanoma, colon carcinoma, and neuroblastoma. However, each agent used as monotherapy induced only a delay in tumor growth. A mechanism for this synergism was suggested because the antitumor response was accompanied by a simultaneous 50% reduction in tumor vessel density and a 5-fold increase in inflammatory cells in the tumor microenvironment. Subsequently, tumor necrosis was demonstrated only in animals receiving the combination therapy, but not when each agent was applied as monotherapy. The results suggest that these synergistic treatment modalities may provide a novel and effective tool for future therapies of metastatic cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.